Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell 9Hematologic Diseases 6Lymphoma, Mantle-Cell 5Leukemia, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Lymphoma 2Leukemia, Lymphoid 2Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1

Interventions

Cyclophosphamide 72Cytarabine 61fludarabine phosphate 48venetoclax 42Peripheral Blood Stem Cell Transplantation 37fludarabine 34Busulfan 31Methotrexate 29Cyclosporine 29Mycophenolic Acid 28Filgrastim 27Azacitidine 27Antilymphocyte Serum 26Whole-Body Irradiation 22Etoposide 21Radiotherapy 20Melphalan 20Tacrolimus 19Rituximab 19Dexamethasone 16Methylprednisolone 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Vincristine 14Cord Blood Stem Cell Transplantation 14Doxorubicin 13Clofarabine 11Mitoxantrone 10ibrutinib 9blinatumomab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × pirtobrutinib × Other hematologic neoplasm × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡